Signed in · PRO
Hologic / Full history

Guidance history, every release

Hologic (HOLX) · 8 releases, May 2, 2024 to Jan 29, 2026 · rows are metrics, columns are releases
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
MetricMay 2, 2024
FY24 Q2
Jul 29, 2024
FY24 Q3
Nov 4, 2024
FY24 Q4
Jan 12, 2025
FY25 Q1
May 1, 2025
FY25 Q2
Jul 30, 2025
FY25 Q3
Nov 3, 2025
FY25 Q4
Jan 29, 2026
FY26 Q1
For FY2025
Non-GAAP earnings per share growth relative to revenue—————New“will grow faster than revenue”——
Organic, constant currency revenue growth excluding COVID—————New“mid-single-digit growth”——
Organic, constant currency revenue growth excluding COVID—————New“mid-single-digit growth”——
Revenue——New“$4,150 - $4,200”—Lowered“$4,050 - $4,100”Narrowed“$4,081 - $4,091”——
Revenue—————New“$1,030 - $1,040”——
Revenue————New“$1,000 - $1,010”———
Revenue——New“$1,025 - $1,035”—————
Revenue Constant Currency % Increase (Decrease)——New“2.3% to 3.5%”—Lowered“0.8% to 2.1%”Narrowed“1.1% to 1.4%”——
Revenue Constant Currency % Increase (Decrease)—————New“3.7% to 4.7%”——
Revenue Constant Currency % Increase (Decrease)————New“(1.0%) to (0.0%)”———
Revenue Constant Currency % Increase (Decrease)——New“0.4% to 1.4%”—————
Revenue Organic % Increase (Decrease)——New“1.7% to 3.0%”—Lowered“(0.7%) to 0.5%”Raised“(0.5%) to (0.2%)”——
Revenue Organic % Increase (Decrease)—————New“2.7% to 3.7%”——
Revenue Organic % Increase (Decrease)————New“(3.5%) to (2.5%)”———
Revenue Organic % Increase (Decrease)——New“(0.2%) to 0.8%”—————
Revenue Organic excluding COVID-19 % Increase (Decrease)——New“3.4% to 4.7%”—Lowered“0.3% to 1.6%”Narrowed“0.6% to 0.8%”——
Revenue Organic excluding COVID-19 % Increase (Decrease)—————New“3.9% to 5.0%”——
Revenue Organic excluding COVID-19 % Increase (Decrease)————New“(2.9%) to (1.8%)”———
Revenue Organic excluding COVID-19 % Increase (Decrease)——New“1.8% to 2.8%”—————
Revenue Reported % Increase (Decrease)——New“3.0% to 4.2%”—Lowered“0.5% to 1.7%”Narrowed“1.3% to 1.5%”——
Revenue Reported % Increase (Decrease)—————New“4.3% to 5.3%”——
Revenue Reported % Increase (Decrease)————New“(1.1%) to (0.1%)”———
Revenue Reported % Increase (Decrease)——New“1.2% to 2.2%”—————
GAAP EPS——New“$3.53 - $3.63”—Lowered“$2.47 - $2.57”Raised“$2.56 - $2.59”——
GAAP EPS—————New“$0.90 - $0.93”——
GAAP EPS————New“$0.85 - $0.88”———
GAAP EPS——New“$0.81 - $0.84”—————
GAAP EPS Reported % Increase (Decrease)——New“6.3% to 9.3%”—Lowered“(25.6%) to (22.6%)”Raised“(22.9%) to (22.0%)”——
GAAP EPS Reported % Increase (Decrease)————New“3.7% to 7.3%”———
GAAP EPS Reported % Increase (Decrease)——New“(21.4%) to (18.4%)”—————
GAAP EPS, Reported % Increase (Decrease)—————New“18.4% to 22.4%”——
Non-GAAP EPS——New“$4.25 - $4.35”—Lowered“$4.15 - $4.25”Raised“$4.23 - $4.26”——
Non-GAAP EPS—————New“$1.09 - $1.12”——
Non-GAAP EPS————New“$1.04 - $1.07”———
Non-GAAP EPS——New“$1.00 - $1.03”—————
Non-GAAP EPS Reported % Increase (Decrease)——New“4.2% to 6.6%”—Lowered“1.7% to 4.2%”Raised“3.7% to 4.4%”——
Non-GAAP EPS Reported % Increase (Decrease)————New“(1.9%) to 0.9%”———
Non-GAAP EPS Reported % Increase (Decrease)——New“2.0% to 5.1%”—————
Non-GAAP EPS, Reported % Increase (Decrease)—————New“7.9% to 10.9%”——
Accelerated share repurchase (ASR) agreement——New“$250 million”—————
Anticipated closing of Gynesonics acquisition——New“first half of calendar year 2025”—————
Diluted shares outstanding————New“approximately 228 million”Reiterated“approximately 228 million”——
Diluted shares outstanding ( basis)——New“approximately 235 million”—————
Diluted shares outstanding assumption————New“approximately 228 million”Reiterated“approximately 228 million”——
Non-GAAP tax rate————New“approximately 19.25%”Reiterated“approximately 19.25%”——
Non-GAAP tax rate ( basis)——New“approximately 19.5%”—————
Non-GAAP tax rate assumption————New“approximately 19.25%”Reiterated“approximately 19.25%”——
For FY2024
Current revenue midpointNew“$4,025 million ($4,022 million in constant currency)”———————
RevenueNew“$4,000 - $4,050”Narrowed“$4,012 - $4,027”——————
Revenue—New“$970 - $985”——————
RevenueNew“$992.5 - $1,007.5”———————
Revenue Constant Currency % Increase (Decrease)New“(0.8%) to 0.4%”Narrowed“(0.5%) to (0.1%)”——————
Revenue Constant Currency % Increase (Decrease)—New“2.9% to 4.5%”——————
Revenue Constant Currency % Increase (Decrease)New“1.2% to 2.7%”———————
Revenue midpointNew“$4,025 million”———————
Revenue midpoint (constant currency)New“$4,022 million”———————
Revenue Organic excluding COVID-19 % IncreaseNew“5.1% to 6.5%”Narrowed“5.2% to 5.6%”——————
Revenue Organic excluding COVID-19 % Increase—New“5.0% to 6.6%”——————
Revenue Organic excluding COVID-19 % IncreaseNew“4.0% to 5.6%”———————
Revenue Reported % Increase (Decrease)New“(0.8%) to 0.5%”Raised“(0.4%) to (0.1%)”——————
Revenue Reported % Increase (Decrease)—New“2.6% to 4.2%”——————
Revenue Reported % Increase (Decrease)New“0.8% to 2.4%”———————
GAAP EPSNew“$3.45 - $3.55”Lowered“$3.37 - $3.44”——————
GAAP EPS—New“$0.80 - $0.87”——————
GAAP EPSNew“$0.80 - $0.87”———————
GAAP EPS - Reported % Increase (Decrease)New“600.0% to 643.8%”———————
GAAP EPS Reported % Increase (Decrease)New“88.5% to 94.0%”Lowered“84.2% to 88.0%”——————
GAAP EPS Reported % Increase (Decrease)—New“116.2% to 135.1%”——————
Non-GAAP EPSNew“$4.02 - $4.12”Narrowed“$4.04 - $4.11”——————
Non-GAAP EPS—New“$0.97 - $1.04”——————
Non-GAAP EPSNew“$0.98 - $1.05”———————
Non-GAAP EPS - Reported % Increase (Decrease)New“5.4% to 12.9%”———————
Non-GAAP EPS Reported % Increase (Decrease)New“1.5% to 4.0%”Narrowed“2.0% to 3.8%”——————
Non-GAAP EPS Reported % Increase (Decrease)—New“9.0% to 16.9%”——————
Diluted shares outstandingNew“approximately 238 million”Reiterated“approximately 238 million”Lowered“approximately 235 million”—————
Impact of four fewer selling days on full-yearNew“a headwind of more than 100 bps”Reiterated“a headwind of more than 100 bps”——————
Non-GAAP tax rateNew“approximately 19.75%”Reiterated“approximately 19.75%”Lowered“approximately 19.5%”—————
Non-GAAP tax rateNew“approximately 19.75%”Reiterated“approximately 19.75%”——————
Selling days headwind factored intoNew“more than 100 bps”———————
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.